- Guardant Health (GH, Financial) to present significant developments in cancer detection at the AACR 2025 Annual Meeting.
- Presentation includes 18 abstracts with focus on multi-cancer detection and multiomic profiling.
- Key advancements in methylation-based cancer detection and tissue molecular profiling will be showcased.
Guardant Health, Inc. (GH), a leader in precision oncology, is set to highlight major advancements in cancer detection and molecular profiling at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30. The company will present 18 abstracts, including four oral sessions, focusing on the potential of its Guardant Infinity™ smart liquid biopsy platform.
The proceedings will feature key data, such as the performance validation of the Shield™ multi-cancer detection (MCD) test, which was selected for the National Cancer Institute's Vanguard Study. Additional presentations will discuss methylation-based cancer identification, lung cancer subtyping, and a real-world data analysis of BRAF mutations in non-small cell lung cancer.
Noteworthy is the analytical validation of a novel tissue profiling assay powered by integrated multiomics, demonstrating a high success rate with minimal tissue input and supporting novel biomarker discovery. New methylation-based applications for liquid biopsy, including molecular subtyping of lung and breast cancer, will also be presented.
Guardant Health's presentations will explore applications in screening, recurrence monitoring, and treatment selection across multiple cancer types. Visit the AACR website for a full list of abstracts and details on Guardant Health's scheduled presentations.
